← Leaderboards
Li Gan
Cornell University
$28,400,728
Attributed
$47,773,243
Total exposure
22
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $10.1M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$58,598,853 · 23
By mechanism
R01$34,602,335 · 13
U54$13,559,533 · 3
RF1$6,109,739 · 1
R56$1,344,626 · 1
R61$1,088,600 · 1
R21$894,569 · 2
Top collaborators
- Yin Shen11 shared
- Hongjun Song7 shared
- Feixiong Cheng5 shared
- Subhash C Sinha5 shared
- Haiyuan Yu5 shared
- John T Lis4 shared
- Yun Li4 shared
- Fei Wang4 shared
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposNeuronsS DiseaseBrainMediatingAffectCellsMicrogliaTau ProteinsGenesInduced Pluripotent Stem CellPathway InteractionsSignal TransductionPlayLinkToxic EffectProteinsTauopathiesMutationPathogenesisMolecularMutantIn VivoCell Type
Grant awards (76)
Elucidate the roles of Alzheimer's disease risk genes and variants in gene expression and AD-related phenotypes$2,393,458
RF1 · FY2025 · AG
Study of Selective Cell and System Vulnerability in Alzheimer's Disease$1,284,439
R01 · FY2025 · AG
Studying NeuroHIV and addictive substances in a human microglia-neuron chimera mouse model$1,088,600
R61 · FY2025 · DA
cGAS inhibitors for Alzheimer's disease treatment$830,547
R01 · FY2025 · AG
Maladaptive antiviral pathways in Alzheimer's disease$799,148
R01 · FY2025 · AG · contact PI
Genome-wide identification and characterization of Alzheimer's Disease-associated enhancers$789,929
R01 · FY2025 · AG
TREM2 Genotype-Informed Drug Repurposing and Combination Therapy Design for AlzheimerÂs Disease$781,379
R01 · FY2025 · AG
Mapping proteomic changes of tauopathy in human neurons$717,709
R01 · FY2025 · AG · contact PI
CH25H mediates microglial neuroinflammation and tau toxicities in AD$711,898
R01 · FY2025 · AG
Mechanisms and intervention of cGAS signaling in brain trauma-induced neuroinflammation and neurodegeneration$654,218
R01 · FY2025 · NS
Study of Selective Cell and System Vulnerability in Alzheimer's Disease$1,320,382
R01 · FY2024 · AG
cGAS inhibitors for Alzheimer's disease treatment$847,498
R01 · FY2024 · AG
Maladaptive antiviral pathways in Alzheimer's disease$810,371
R01 · FY2024 · AG · contact PI
TREM2 Genotype-Informed Drug Repurposing and Combination Therapy Design for AlzheimerÂs Disease$809,747
R01 · FY2024 · AG
Genome-wide identification and characterization of Alzheimer's Disease-associated enhancers$806,051
R01 · FY2024 · AG
Acetylated Tau Immunotherapy for Alzheimer's Disease$499,911
R41 · FY2024 · AG
Study of Selective Cell and System Vulnerability in Alzheimer's Disease$1,356,754
R01 · FY2023 · AG
cGAS inhibitors for Alzheimer's disease treatment$847,498
R01 · FY2023 · AG
Maladaptive antiviral pathways in Alzheimer's disease$834,101
R01 · FY2023 · AG · contact PI
TREM2 Genotype-Informed Drug Repurposing and Combination Therapy Design for AlzheimerÂs Disease$817,408
R01 · FY2023 · AG
Genome-wide identification and characterization of Alzheimer's Disease-associated enhancers$806,051
R01 · FY2023 · AG
Optimizing virtual hits of human CGAS inhibitors to treat neurodegeneration$499,540
R43 · FY2023 · AG
Elucidate the roles of Alzheimer's disease risk genes and variants in gene expression and AD-related phenotypes$3,716,281
RF1 · FY2022 · AG
Study of Selective Cell and System Vulnerability in Alzheimer's Disease$1,344,626
R56 · FY2022 · AG
cGAS inhibitors for Alzheimer's disease treatment$847,498
R01 · FY2022 · AG · contact PI
TREM2 Genotype-Informed Drug Repurposing and Combination Therapy Design for AlzheimerÂs Disease$831,528
R01 · FY2022 · AG
Maladaptive antiviral pathways in Alzheimer's disease$830,711
R01 · FY2022 · AG · contact PI
Genome-wide identification and characterization of Alzheimer's Disease-associated enhancers$806,365
R01 · FY2022 · AG
cGAS inhibitors for Alzheimer's disease treatment$847,498
R01 · FY2021 · AG · contact PI
Functional characterization of Alzheimer's disease associated genetic variants$831,005
R01 · FY2021 · AG
Maladaptive antiviral pathways in Alzheimer's disease$830,711
R01 · FY2021 · AG · contact PI
Tau acetylation in Alzheimer's disease$506,388
R01 · FY2021 · AG · contact PI
Linking tau proteostasis with neuronal activity in FTD$2,043,639
U54 · FY2020 · NS · contact PI
Functional characterization of Alzheimer's disease associated genetic variants$833,789
R01 · FY2020 · AG
Tau acetylation in Alzheimer's disease$588,158
R01 · FY2020 · AG · contact PI
Project 1: Aberrant neuronal activity and tau distribution in FTD$345,495
U54 · FY2020 · NS · contact PI
Core A: Administrative Core$148,705
U54 · FY2020 · NS · contact PI
Linking tau proteostasis with neuronal activity in FTD$2,043,636
U54 · FY2019 · NS · contact PI
Functional characterization of Alzheimer's disease associated genetic variants$836,490
R01 · FY2019 · AG
Tau acetylation in Alzheimer's disease$588,158
R01 · FY2019 · AG · contact PI
Molecular mechanisms in progranulin deficient frontotemporal dementia$451,202
R01 · FY2019 · AG · contact PI
Project 1: Aberrant neuronal activity and tau distribution in FTD$345,493
U54 · FY2019 · NS · contact PI
Core A: Administrative Core$148,702
U54 · FY2019 · NS · contact PI
Linking tau proteostasis with neuronal activity in FTD$2,149,676
U54 · FY2018 · NS · contact PI
Functional characterization of Alzheimer's disease associated genetic variants$833,263
R01 · FY2018 · AG
Molecular mechanisms in progranulin deficient frontotemporal dementia$503,909
R01 · FY2018 · AG · contact PI
Tau acetylation in Alzheimer's disease$482,479
R01 · FY2018 · AG · contact PI
Tau acetylation in Alzheimer's disease$482,479
R01 · FY2018 · AG · contact PI
Project 1: Aberrant neuronal activity and tau distribution in FTD$394,504
U54 · FY2018 · NS · contact PI
Core A: Administrative Core$152,418
U54 · FY2018 · NS · contact PI
Linking tau proteostasis with neuronal activity in FTD$2,318,392
U54 · FY2017 · NS · contact PI
Functional characterization of Alzheimer's disease associated genetic variants$857,493
R01 · FY2017 · AG
Tau acetylation in Alzheimer's disease$618,691
R01 · FY2017 · AG · contact PI
Molecular mechanisms in progranulin deficient frontotemporal dementia$503,909
R01 · FY2017 · AG · contact PI
Project 1: Aberrant neuronal activity and tau distribution in FTD$426,869
U54 · FY2017 · NS · contact PI
Core A: Administrative Core$154,797
U54 · FY2017 · NS · contact PI
Linking tau proteostasis with neuronal activity in FTD$14,503
U54 · FY2017 · NS · contact PI
Linking tau proteostasis with neuronal activity in FTD$2,255,764
U54 · FY2016 · NS · contact PI
Molecular mechanisms in progranulin deficient frontotemporal dementia$503,909
R01 · FY2016 · AG · contact PI
Project 1: Aberrant neuronal activity and tau distribution in FTD$427,900
U54 · FY2016 · NS · contact PI
SIRT1 Limits Microglial Toxicity in Alzheimer's Disease$407,785
R01 · FY2016 · AG · contact PI
Core A: Administrative Core$189,040
U54 · FY2016 · NS · contact PI
Molecular mechanisms in progranulin deficient frontotemporal dementia$503,909
R01 · FY2015 · AG · contact PI
SIRT1 Limits Microglial Toxicity in Alzheimer's Disease$395,551
R01 · FY2015 · AG · contact PI
Screening for inhibitors of p300-mediated tau acetylation for Alzheimer's Disease$245,895
R21 · FY2015 · AG
SIRT1 Limits Microglial Toxicity in Alzheimer's Disease$407,785
R01 · FY2014 · AG · contact PI
The Role of Cathepsin B and Cystatin C in Alzheimer's Disease$371,768
R01 · FY2014 · AG · contact PI
Screening for inhibitors of p300-mediated tau acetylation for Alzheimer's Disease$221,600
R21 · FY2014 · AG
SIRT1 Limits Microglial Toxicity in Alzheimer's Disease$385,358
R01 · FY2013 · AG · contact PI
The Role of Cathepsin B and Cystatin C in Alzheimer's Disease$351,322
R01 · FY2013 · AG · contact PI
SIRT1 Limits Microglial Toxicity in Alzheimer's Disease$407,785
R01 · FY2012 · AG · contact PI
The Role of Cathepsin B and Cystatin C in Alzheimer's Disease$371,768
R01 · FY2012 · AG · contact PI
The Role of Cathepsin B and Cystatin C in Alzheimer's Disease$371,768
R01 · FY2011 · AG · contact PI
The Role of Cathepsin B and Cystatin C in Alzheimer's Disease$386,775
R01 · FY2010 · AG · contact PI
Cathepsin B and cystatin C in AD-related neuronal damage$195,413
R21 · FY2005 · AG
Cathepsin B and cystatin C in AD-related neuronal damage$231,661
R21 · FY2004 · AG